Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA

Background: Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective. Aim: To report the experience in our Health Centre with rapamycin-eluting stents. Patients and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruiz B,Carolina, Delgado D,Mario, Martinez C,Carolina, Valdivieso V,Alicia, Aylwin H,Carmen Gloria, Deck R,Carlos, Alcaino I,Milton
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2007
Materias:	Angioplasty Sirolimus Stents
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000500004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872007000500004
record_format	dspace
spelling	oai:scielo:S0034-988720070005000042007-07-09Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECARuiz B,CarolinaDelgado D,MarioMartinez C,CarolinaValdivieso V,AliciaAylwin H,Carmen GloriaDeck R,CarlosAlcaino I,Milton Angioplasty Sirolimus Stents Background: Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective. Aim: To report the experience in our Health Centre with rapamycin-eluting stents. Patients and methods: Forty two stents with rapamicine were implanted to 32 diabetic patients, between June 2002 and December 2004. After the procedure, subjects were clinically followed-up for an average period of 19.9+9.9 months, evaluating functional capacity, angina pectoris, dyspnea, need for hospital admission, acute coronary events and cardiac death. In those subjects clinically suspected to have restenosis, a coronary angiography was performed. Results: Twenty-nine subjects (90.6%) remained asymptomatic, two subjects (6.3%) developed angina pectoris but restenosis was ruled out, and one subject (3.1%) died. Conclusions: The use of rapamycin-eluting stents in these patients was safe and successful with no evidence of clinic restenosis. These positive results are similar to those reported in the Diabetes Studyinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.135 n.5 20072007-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000500004es10.4067/S0034-98872007000500004
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Angioplasty Sirolimus Stents
spellingShingle	Angioplasty Sirolimus Stents Ruiz B,Carolina Delgado D,Mario Martinez C,Carolina Valdivieso V,Alicia Aylwin H,Carmen Gloria Deck R,Carlos Alcaino I,Milton Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA
description	Background: Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective. Aim: To report the experience in our Health Centre with rapamycin-eluting stents. Patients and methods: Forty two stents with rapamicine were implanted to 32 diabetic patients, between June 2002 and December 2004. After the procedure, subjects were clinically followed-up for an average period of 19.9+9.9 months, evaluating functional capacity, angina pectoris, dyspnea, need for hospital admission, acute coronary events and cardiac death. In those subjects clinically suspected to have restenosis, a coronary angiography was performed. Results: Twenty-nine subjects (90.6%) remained asymptomatic, two subjects (6.3%) developed angina pectoris but restenosis was ruled out, and one subject (3.1%) died. Conclusions: The use of rapamycin-eluting stents in these patients was safe and successful with no evidence of clinic restenosis. These positive results are similar to those reported in the Diabetes Study
author	Ruiz B,Carolina Delgado D,Mario Martinez C,Carolina Valdivieso V,Alicia Aylwin H,Carmen Gloria Deck R,Carlos Alcaino I,Milton
author_facet	Ruiz B,Carolina Delgado D,Mario Martinez C,Carolina Valdivieso V,Alicia Aylwin H,Carmen Gloria Deck R,Carlos Alcaino I,Milton
author_sort	Ruiz B,Carolina
title	Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA
title_short	Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA
title_full	Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA
title_fullStr	Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA
title_full_unstemmed	Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA
title_sort	angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: experiencia del hospital dipreca
publisher	Sociedad Médica de Santiago
publishDate	2007
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000500004
work_keys_str_mv	AT ruizbcarolina angioplastiaconstentsliberadoresderapamicinaendiabeticostipo2experienciadelhospitaldipreca AT delgadodmario angioplastiaconstentsliberadoresderapamicinaendiabeticostipo2experienciadelhospitaldipreca AT martinezccarolina angioplastiaconstentsliberadoresderapamicinaendiabeticostipo2experienciadelhospitaldipreca AT valdiviesovalicia angioplastiaconstentsliberadoresderapamicinaendiabeticostipo2experienciadelhospitaldipreca AT aylwinhcarmengloria angioplastiaconstentsliberadoresderapamicinaendiabeticostipo2experienciadelhospitaldipreca AT deckrcarlos angioplastiaconstentsliberadoresderapamicinaendiabeticostipo2experienciadelhospitaldipreca AT alcainoimilton angioplastiaconstentsliberadoresderapamicinaendiabeticostipo2experienciadelhospitaldipreca
_version_	1718436319505416192

Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA

Ejemplares similares